Cancer treatment device

Abstract

To provide a new cancer treatment device effective in treatment of cancer.SOLUTION: In a cancer treatment device 30, a treatment tool 32 is introduced to the vicinity of an affected part via a working channel of an endoscope. A deep ultraviolet LED 34 is arranged at a distal end 40 of the treatment tool 32, and emits deep ultraviolet rays to be applied to the affected part. An X-ray opaque marker 44 is arranged the distal end of the treatment tool. A control part 36 controls light emission of the deep ultraviolet LED. The control part 36 is arranged at a proximal end 42 of the treatment tool 32. A lead wire 38 connecting the deep ultraviolet LED 34 and the control part 36 is arranged inside the treatment tool 32.SELECTED DRAWING: Figure 2

Description

Technical Field

[0001] The present invention relates to an apparatus for cancer treatment.

Background Art

[0002] As treatment methods for early esophageal cancer, gastric cancer, colorectal cancer, etc., endoscopic mucosal resection and endoscopic submucosal dissection are performed. Photodynamic therapy (PDT) that administers a photosensitive substance is clinically applied in Japan for residual recurrent esophageal cancer. In addition, photoimmunotherapy (NIR-PIT) that administers a near-infrared photosensitive substance to a molecular target antibody drug and accumulates it in cancer and then kills the cancer with near-infrared light is in clinical development. As an example of other phototherapies, Patent Document 1 discloses a method of irradiating tumor cells with pulsed light (UV pulse flash) having a continuous emission spectrum ranging from 230 to 270 nm to selectively kill tumor cells. In the method of Patent Document 1, a xenon flash lamp is adopted as the light source of the UV pulse flash.

Prior Art Documents

Patent Documents

[0003]

Patent Document 1

Summary of the Invention

Problems to be Solved by the Invention

[0004] Endoscopic mucosal resection and endoscopic submucosal dissection are not applicable to lesions with ulcers, and surgical operations may be required due to bleeding or perforation during endoscopic resection. Most digestive organ cancers are adenocarcinomas, but generally, radiotherapy is considered ineffective for adenocarcinomas. In addition, in photodynamic therapy (PDT), photosensitivity occurs as a side effect of the photosensitive substance used, imposing a large burden on patients. Therefore, effective treatment methods for these have not yet been established.

[0005] This disclosure is made in light of these circumstances, and its purpose is to provide a new cancer treatment device that is effective in treating cancer. [Means for solving the problem]

[0006] One aspect of this disclosure is a cancer treatment device. This cancer treatment device includes a deep ultraviolet LED that emits deep ultraviolet light for irradiating the affected area. [Effects of the Invention]

[0007] This disclosure provides a novel cancer treatment device that is effective in treating cancer. [Brief explanation of the drawing]

[0008] [Figure 1] This diagram schematically shows the configuration of a cancer treatment device according to the first embodiment. [Figure 2] Figure 2(a) is a schematic diagram showing the configuration of the cancer treatment device according to the second embodiment. Figure 2(b) is an enlarged schematic view showing the configuration of the distal end of the cancer treatment device according to the second embodiment. [Figure 3] This diagram schematically shows a cancer treatment device according to a second embodiment that irradiates cancer with deep ultraviolet light. [Figure 4] This is an enlarged diagram schematically showing the configuration of the distal end of a cancer treatment device according to a modification of the second embodiment. [Figure 5] This figure shows the changes in cell morphology of human pancreatic cancer cell lines KP-4, PANC-1, and KLM-1 after deep ultraviolet irradiation. [Figure 6] This figure shows the induction of apoptosis in human pancreatic cancer cell lines KP-4, PANC-1, and KLM-1 by deep ultraviolet light. [Figure 7] Figures 7(a) and 7(b) show the changes in protein expression in the human pancreatic cancer cell line KLM1 after deep ultraviolet irradiation. [Figure 8]Figure 8(a) shows the results of real-time PCR on TIMP1 expression in the human pancreatic cancer cell line KLM-1. Figure 8(b) shows the results of real-time PCR on TSP1 expression in the human pancreatic cancer cell line KLM-1. [Figure 9] This figure shows the changes in YAP / TAZ expression in the human pancreatic cancer cell line KLM1. [Figure 10] These are images of tumors in mouse subcutaneous carcinogenesis models 14 days after irradiation in groups receiving deep ultraviolet light once a week, groups receiving it once a week for two consecutive weeks, and a no-irradiation group. [Figure 11] This graph shows the change in tumor volume in a mouse subcutaneous carcinogenesis model based on the number of deep ultraviolet irradiation sessions. [Figure 12] This graph shows the expression levels of elastin as analyzed by immunohistochemistry. [Figure 13] This graph shows the expression levels of collagen I as analyzed by immunohistochemistry. [Figure 14] This graph shows the expression levels of collagen IV as analyzed by immunohistochemistry. [Modes for carrying out the invention]

[0009] The embodiments for implementing this disclosure will be described in detail below with reference to the drawings and other figures. The embodiments are illustrative and not limiting to the invention, and not all features or combinations thereof described in the embodiments are necessarily essential to the invention.

[0010] [First Embodiment] Figure 1 schematically shows the configuration of a cancer treatment device according to the first embodiment. As shown in Figure 1, the cancer treatment device 10 comprises a deep ultraviolet LED 12, a holding unit 14, a control unit 16, a conductor 18, and an imaging unit 20.

[0011] The deep ultraviolet LED 12 emits deep ultraviolet rays that irradiate the affected area. The deep ultraviolet LED 12 has an LED structure in which a nitride semiconductor made of GaN, InGaN, or AlGaN is crystal-grown in layers on a sapphire substrate, similar to a blue LED. The deep ultraviolet LED 12 is small, about several millimeters in size, has a low operating voltage, and a zero warm-up time. Furthermore, the deep ultraviolet LED 12 has a long lifespan. Therefore, the cancer treatment device 10 of this embodiment has the advantages of being small and having low energy consumption.

[0012] Deep ultraviolet rays are ultraviolet rays with a relatively short wavelength of 250 to 350 nm and have a cell-damaging effect. This is because DNA has an absorption wavelength peak for ultraviolet rays around 260 to 270 nm, and mutations occur due to ultraviolet rays of this wavelength, causing two adjacent thymines or cytosines to form dimers, leading to functional disorders such as inhibition of cell division. Because deep ultraviolet rays have a short wavelength, the depth of penetration into tissues is limited (for example, less than 2 mm from the mucosal epithelium), and it is considered that the anti-cancer effect at deeper positions is limited. However, in the present invention, it has been found that it also has an anti-cancer effect on cancer tissues existing deeper than that depth. Specifically, deep ultraviolet rays act not only on cancer cells themselves but also on the fibrous components (such as elastin and collagen) of tumors, reducing these fibrous components and shrinking tumors.

[0013] The wavelength of the deep ultraviolet rays emitted by the deep ultraviolet LED 12 is preferably 350 nm or less, more preferably 250 to 300 nm, and even more preferably 260 to 290 nm.

[0014] The output, number, and size of the deep ultraviolet LED 12 can be appropriately selected according to the location of the affected area and the size of the affected area. From the perspective of reliably obtaining an anti-tumor effect by deep ultraviolet rays, the deep ultraviolet LED 12 is preferably configured to irradiate the affected area with deep ultraviolet rays at an illuminance of 2 mW / cm 2 or more for 5 to 300 seconds. The illuminance of the deep ultraviolet rays is more preferably 2 to 7 mW / cm 2For example, the illuminance in the central part of the illuminance distribution formed by the deep ultraviolet LED 12 is set to be the illuminance applied to the affected area, with the illuminance in that central part being 2-7 mW / cm². 2 The deep ultraviolet LED 12 can be configured as described above. The irradiation time for deep ultraviolet light is more preferably 15 to 120 seconds, and even more preferably 30 to 60 seconds. One irradiation is effective, but two or more irradiations are preferable to ensure an antitumor effect. The irradiation interval can be appropriately changed in hours, days, weeks, or months depending on the condition of the tumor in the affected area and the impact on normal tissue.

[0015] The holding part 14 holds the deep ultraviolet LED 12 and fixes it so that deep ultraviolet light can be irradiated from near the affected area. The holding part 14 may have an elongated shape that can be inserted close to the affected area inside the body. This allows deep ultraviolet light to be irradiated only to the affected area inside the body. The length of the holding part 14 can be adjusted so that the deep ultraviolet LED 12 can reach close to the affected area. The diameter of the holding part 14 can be adjusted according to the location of the affected area inside the body. For example, it can be made to be wide enough to pass through a laparoscope port or the digestive tract.

[0016] In the first embodiment shown in Figure 1, a deep ultraviolet LED 12 is positioned at one end (distal end) of the holding portion 14. A control unit 16 for controlling the emission of light from the deep ultraviolet LED 12 is positioned at the end (proximal end) of the holding portion 14 opposite to the end where the deep ultraviolet LED 12 is positioned. A conductor 18 connecting the deep ultraviolet LED 12 and the control unit 16 is positioned inside the holding portion 14. The holding portion 14 may be made of a rigid material such as metal, or a flexible material such as resin fiber. Furthermore, a part of the holding portion 14 may be made bendable. For example, the part of the holding portion 14 near the end where the deep ultraviolet LED 12 is positioned may be made bendable so that the deep ultraviolet light emitted by the deep ultraviolet LED 12 can be accurately directed to the affected area.

[0017] An imaging unit 20, which outputs image information captured from inside the body as an electrical signal, is positioned at the end of the holding unit 14 where the deep ultraviolet LED 12 is located. The imaging unit 20 may include an image sensor such as a CCD or CMOS. Based on the image information obtained from the imaging unit 20, the position of the deep ultraviolet LED 12 at the tip of the holding unit 14 relative to the affected area can be determined, and the deep ultraviolet LED 12 can be positioned to face the affected area, allowing for accurate irradiation of the affected area with deep ultraviolet light.

[0018] The cancer treatment device 10 according to the first embodiment can be used to treat various types of cancer, but is particularly useful for treating adenocarcinoma. As described above, deep ultraviolet light has not only cytotoxic effects but also antitumor effects beyond its tissue penetration. This antitumor effect is particularly effective against adenocarcinoma.

[0019] The cancer treatment device 10 may be an endoscope. If the cancer treatment device 10 is an endoscope, a portion of the holding unit 14 is inserted into the body, starting with the distal end of the holding unit 14, which houses the deep ultraviolet LED 12 and the imaging unit 20. The distal end of the holding unit 14 can be inserted to the vicinity of the affected area while viewing the inside of the body using the imaging unit 20. After that, deep ultraviolet light can be irradiated onto the affected area from the deep ultraviolet LED 12 to treat the cancer. The type of endoscope is not particularly limited and includes flexible endoscopes such as gastrointestinal endoscopes and rigid endoscopes such as laparoscopes.

[0020] [Second Embodiment] Figure 2(a) schematically shows the configuration of the cancer treatment device according to the second embodiment. Figure 2(b) schematically shows the configuration of the distal end of the cancer treatment device according to the second embodiment. As shown in Figures 2(a) and 2(b), the cancer treatment device 30 comprises a treatment instrument 32, a deep ultraviolet LED 34, a control unit 36, and a conductor 38.

[0021] The treatment instrument 32 is wire-shaped and is introduced to the vicinity of the affected area via the working channel of the endoscope. The treatment instrument 32 is made of a flexible material such as a resin fiber. The size of the treatment instrument 32 can be appropriately set so that it can pass through the working channel of the endoscope and its distal end can reach the vicinity of the affected area. For example, the longest width of the cross-section of the treatment instrument 32 is 2.7 mm or less.

[0022] As shown in Figure 2(b), the deep ultraviolet LED 34 is positioned at the distal end 40 of the treatment instrument 32. Cancer is often found within the walls of tubes inside the body. Therefore, to ensure that the deep ultraviolet LED can be reliably irradiated onto the cancer, it is preferable that the deep ultraviolet LED 34 be positioned to emit deep ultraviolet light from the side of the treatment instrument 32.

[0023] As shown in Figure 2(a), a control unit 36 ​​for controlling the emission of the deep ultraviolet LED 34 is located at the proximal end 42 of the treatment instrument 32. As shown in Figure 2(b), a wire 38 connecting the deep ultraviolet LED 12 and the control unit 16 is located inside the treatment instrument 32. The configurations of the deep ultraviolet LED 34, the control unit 36, and the wire 38 can be the same as those of the deep ultraviolet LED 12, the control unit 16, and the wire 18 in the first embodiment.

[0024] As shown in Figure 2(b), an X-ray opaque marker 44 is positioned at the distal end 40 of the treatment instrument 32. The X-ray opaque marker 44 is made of a material that does not transmit X-rays. Examples of such materials include metals such as gold, platinum, or tantalum, as well as resins containing barium sulfate, barium carbonate, halogen-containing compounds, or fillers (such as tricalcium phosphate or hydroxyapatite). The X-ray opaque marker 44 allows for easy confirmation of the position of the distal end 40 of the treatment instrument 32 within the body under X-ray fluoroscopy. The position and shape of the X-ray opaque marker 44 at the distal end 40 of the treatment instrument 32 are not limited to those shown in Figure 2(b), but are acceptable as long as the position and shape allow for confirmation of the position of the distal end 40 of the treatment instrument 32 under X-ray fluoroscopy.

[0025] Figure 3 is a schematic diagram of a cancer treatment device according to a second embodiment, which irradiates cancer with deep ultraviolet light. Figure 3 shows an endoscope 100, duodenum 110, pancreas 112, and bile duct 114 to illustrate the treatment of cancer 120 by the treatment instrument 32 of the cancer treatment device 30 according to the second embodiment. As shown in Figure 3, the treatment instrument 32 of the cancer treatment device 30 according to the second embodiment is introduced into the body via a working channel (not shown) of the endoscope 100. The tip of the endoscope 100 is introduced to the vicinity of the point where the duodenum 110 connects to the bile duct. The distal end 40 of the treatment instrument 32 is introduced from the tip of the endoscope 100 to the vicinity of the cancer 120 in the bile duct 114. The introduction of this distal end 40 is performed under X-ray fluoroscopy, while confirming the position of the distal end 40 in the body using an X-ray radiopaque marker 44 (not shown). Deep ultraviolet A light is irradiated onto the cancer 120 from a deep ultraviolet LED 34 (not shown) located at the distal end 40 of the treatment device 32 to treat the cancer 120. In this embodiment, the cancer 120 is, for example, biliary tract cancer (bile duct cancer, gallbladder cancer).

[0026] [Differentiation] The cancer treatment apparatus according to the second embodiment of this disclosure comprises a treatment instrument, a deep ultraviolet LED, a control unit, a conductor, and an X-ray opaque marker, similar to the second embodiment. The same reference numerals are used for components common to the cancer treatment apparatus 30 according to the second embodiment, and redundant explanations are omitted as appropriate.

[0027] Figure 4 schematically shows the configuration of the distal end of the treatment instrument of a modified cancer treatment device according to the second embodiment. The cancer treatment device 50 according to the modified second embodiment differs from the cancer treatment device 30 shown in Figure 2(b) in that deep ultraviolet LEDs 54a, 54b, and 54c are arranged on the side of the treatment instrument 32 such that they are aligned in a line in the direction of introduction of the treatment instrument 52 at the distal end 60 of the treatment instrument 52. The deep ultraviolet LEDs 54a, 54b, and 54c are connected to a control unit 36 ​​(not shown) by a conductor 56. An X-ray opaque marker 44 is located at the distal end 60 of the treatment instrument 52. By bending the side of the treatment instrument 52 on which the deep ultraviolet LEDs 54a, 54b, and 54c are located, the deep ultraviolet light emitted from the deep ultraviolet LEDs 54a, 54b, and 54c can be concentrated on the cancer. This allows for more efficient irradiation of the cancer with deep ultraviolet light to treat the cancer.

[0028] [Third Embodiment] A cancer treatment method according to the third embodiment of this disclosure includes the step of irradiating the affected area of ​​a subject with deep ultraviolet light emitted from a deep ultraviolet LED. According to this embodiment, cancer can be effectively treated with energy savings by irradiating with deep ultraviolet light using a deep ultraviolet LED.

[0029] The output, size, and number of deep ultraviolet LEDs can be appropriately selected according to the required illuminance for treatment. The irradiation distance from the deep ultraviolet LEDs to the affected area can also be appropriately selected according to the required illuminance for treatment. From the viewpoint of accurately delivering deep ultraviolet light to the affected area, an irradiation distance of 1 cm or less is preferable.

[0030] The wavelength, illuminance, irradiation time, number of irradiations, and irradiation interval of deep ultraviolet light can be set in the same manner as described in the embodiments of the cancer treatment device described above. In one embodiment of the cancer treatment method, it is preferable to use the cancer treatment device according to the above embodiment to irradiate the affected area of ​​the patient with deep ultraviolet light.

[0031] In one embodiment of the cancer treatment method, the cancer may be of various types, preferably adenocarcinoma. As described above, the antitumor effect of deep ultraviolet light is particularly effective against adenocarcinoma. [Examples]

[0032] The embodiments will be described in more detail below with reference to examples, but these examples do not limit the present disclosure in any way.

[0033] Deep ultraviolet (UV) irradiation was performed using a prototype deep UV LED irradiation module from Nikkiso Co., Ltd. This module is capable of irradiating deep UV in the 250-350 nm range, with the wavelength used in this example being 285 nm. UVA irradiation was performed using a UVA irradiator (product name: UV LED (PW-UV943H-04), manufactured by Nichia Corporation) that emits UVA at a wavelength of 375 nm. Because the wavelengths of UV emitted by the deep UV irradiator and the UVA irradiator are different, the irradiance was 6.7 mW / cm². 2 To achieve this, the irradiation distance was set to 3.0 cm for the deep ultraviolet irradiator and 4.7 cm for the UVA irradiator.

[0034] The human pancreatic cancer cell lines KP-4, PANC-1, and KLM-1 were obtained from the Medical Cell Resource Center, Institute of Development, Aging and Cancer, Tohoku University.

[0035] (Example 1) Human pancreatic cancer cell lines KP-4, PANC-1, and KLM-1 were irradiated with deep ultraviolet (DUV) or UVA light for 30 seconds, and changes in cell morphology 24 hours after irradiation were observed using an all-in-one fluorescence microscope (product name: BZ-H4XD, Keyence). Figure 5 shows the changes in cell morphology of human pancreatic cancer cell lines KP-4, PANC-1, and KLM-1 after DUV irradiation. In all cell types, the DUV-irradiated group showed deformation of cell structure and induction of cell death compared to the UVA-irradiated group and the unirradiated control group.

[0036] (Example 2) In this study, the ability of deep ultraviolet (DUV) light to induce apoptosis in human pancreatic cancer cell lines KP-4, PANC-1, and KLM-1 was investigated. The study was conducted using the Muse® Annexin V and Dead Cell Kit (Millipore) according to the manufacturer's protocol. Figure 6 shows the induction of apoptosis in human pancreatic cancer cell lines KP-4, PANC-1, and KLM-1 by DUV light. After 30 seconds of DUV irradiation, the DUV irradiation group showed apoptosis rates of 80.9% for KLM1, 92.1% for Panc1, and 88.0% for KP4, which was significantly higher than the UVA irradiation group and the unirradiated control group.

[0037] (Example 3) To elucidate a novel mechanism of the antitumor effect of deep ultraviolet (DUV) radiation, proteomic analysis was performed using the Angiogenesis Antibody Assay Kit (R&D Systems) to examine changes in protein expression thought to be involved in angiogenesis and cancer invasion, rather than DNA damage. The proteomic analysis was performed according to the manufacturer's protocol. Figures 7(a) and 7(b) show changes in protein expression in the human pancreatic cancer cell line KLM1 after DUV irradiation. In Figure 7(a), the area enclosed by the dotted circle shows the expression of the TIMP1 (Tissue Inhibitor of Metalloproteinases 1) protein. From Figure 7(a), it can be seen that DUV irradiation suppresses TIMP1 expression. TIMP1 is a protein thought to inhibit extracellular organode-degrading enzymes. In Figure 7(b), the area enclosed by the dotted circle shows the expression of the TSP1 (Thrombospondin 1) protein, which is thought to be involved in cancer invasiveness. From Figure 7(b), it can be seen that DUV irradiation suppresses TSP1 expression.

[0038] The expression of TIMP1 and TSP1 was also investigated using real-time PCR. Real-time PCR was performed using TIMP1 primers (assay identification no. Hs99999139_m1; Applied Biosystems), TSP1 (THBS1) primers (assay identification no. Hs00962908_m1; Applied Biosystems), TaqMan universal PCR master mix (Applied Biosystems), and the 7300 Fast Real Time PCR System (Applied Biosystems). An 18S rRNA primer (assay identification no. Hs99999901_s1; Applied Biosystems) was used as an endogenous control. Figure 8(a) shows the results of real-time PCR for TIMP1 expression in the human pancreatic cancer cell line KLM-1. Figure 8(b) shows the results of real-time PCR for TSP1 expression in the human pancreatic cancer cell line KLM-1. As shown in Figures 8(a) and 8(b), significant suppression of TIMP1 and TSP1 expression was observed in the deep ultraviolet irradiation group compared to the UVA irradiation group and the control group (unirradiated).

[0039] (Example 4) The association between TIMP and YAP (Yes-associated protein) / TAZ (Transcriptional co-activator with PDZ-binding motif), which promotes cell proliferation and suppresses cell death, has been reported. Therefore, YAP / TAZ expression in KLM1 cells was examined over time by Western blotting in deep ultraviolet irradiation, UVA irradiation, and a control group (unirradiated). Western blotting was performed using a YAP / TAZ antibody (8418S; Cell Signaling Technology), a β-actin antibody (A5441; Sigma), and the ChemiDoc® Touch imaging system (BIO RAD). Figure 9 shows the changes in YAP / TAZ expression in the human pancreatic cancer cell line KLM1. YAP / TAZ expression almost disappeared 3 hours after deep ultraviolet irradiation of KLM1 cells.

[0040] (Example 5) As an animal model for cancer, a mouse subcutaneous carcinogenesis model was created by subcutaneous transplantation of the pancreatic cancer cell line KLM1. Specifically, 1x10 KLM1 cells were transplanted subcutaneously into the thigh of nude mice (BALB / c: male, 8 weeks old). 7 The cells were mixed with 100 μl of cell matrix (Nitta Gelatin Co., Ltd.) and transplanted by subcutaneous injection. Tumor size was examined over time in the group receiving deep ultraviolet (DUV) irradiation once a week, the group receiving DUV irradiation once a week for two consecutive weeks, and the control group (no irradiation). Figure 10 shows photographs of the tumors in the mouse subcutaneous carcinogenesis model on day 14 of irradiation in the DUV irradiation once a week group, the group receiving DUV irradiation once a week for two consecutive weeks, and the control group (no irradiation). Figure 11 is a graph showing the change in tumor volume in the mouse subcutaneous carcinogenesis model with respect to the number of DUV irradiation sessions. Both the group receiving DUV irradiation once a week and the group receiving DUV irradiation once a week for two consecutive weeks showed an inhibitory effect on tumor growth compared to the control group (no irradiation). Furthermore, the group receiving DUV irradiation once a week for two consecutive weeks showed a tendency for growth to be suppressed more than the group receiving DUV irradiation once a week.

[0041] (Example 6) We investigated the expression of elastin, collagen I, and collagen IV, which are involved in cell proliferation, in subcutaneous tumors using immunohistochemistry. Immunohistochemistry was performed using elastin antibody (AB213720; abcam), collagen I antibody (AB138492; abcam), collagen IV antibody (ab6586; abcam), and The Discovery XT automated slide preparation system (Ventana Medical Systems).

[0042] Figure 12 is a graph showing elastin expression levels analyzed by immunohistochemistry. Significant suppression of expression was observed in the group exposed to deep ultraviolet light once a week for two consecutive weeks. In this irradiation group, elastin expression was suppressed more than in the single-treatment group. Figure 13 is a graph showing collagen I expression levels analyzed by immunohistochemistry. Similarly, collagen I expression was significantly suppressed in the group exposed to deep ultraviolet light once a week for two consecutive weeks, and was more suppressed than in the single-treatment group. Figure 14 is a graph showing collagen IV expression levels analyzed by immunohistochemistry. Collagen IV expression was suppressed by deep ultraviolet light, but there was no significant difference between the group exposed to deep ultraviolet light once a week for two consecutive weeks and the single-treatment group.

[0043] Studies using human pancreatic cancer cell lines and a mouse subcutaneous carcinogenesis model demonstrated that deep ultraviolet (UV) LEDs possessed antitumor effects. These results suggest the potential of a new cancer treatment using UV LEDs.

[0044] The present disclosure has been described above based on embodiments. These embodiments are illustrative, and it will be understood by those skilled in the art that various modifications are possible in combinations of their components and processing processes, and that such modifications are also within the scope of the present disclosure. [Explanation of Symbols]

[0045] 30 Cancer treatment device, 32 Treatment instrument, 34 Deep ultraviolet LED, 36 Control unit, 38 Wire, 40 Distal end, 42 Proximal end, 44 Radiopaque marker.

Claims

1. A cancer treatment device comprising a deep ultraviolet LED that emits deep ultraviolet light for irradiating the affected area, wherein the wavelength of the deep ultraviolet light is 285 to 350 nm, and the deep ultraviolet light of the said wavelength reduces the fibrous components of the tumor.

2. The cancer treatment device according to claim 1, further comprising a treatment instrument introduced to the vicinity of the affected area via the working channel of an endoscope, wherein the deep ultraviolet LED is located at the distal end of the treatment instrument.

3. The cancer treatment device according to claim 2, characterized in that the deep ultraviolet LED is positioned at the distal end of the treatment instrument so as to emit deep ultraviolet light from the side of the treatment instrument.

4. The cancer treatment device according to claim 2 or 3, characterized in that the longest width of the cross-section of the treatment instrument is 2.7 mm or less.

5. The cancer treatment device according to any one of claims 2 to 4, further comprising an X-ray radiopaque marker, wherein the X-ray radiopaque marker is located at the distal end of the treatment instrument.

6. The cancer treatment device according to any one of claims 2 to 5, comprising two or more deep ultraviolet LEDs, wherein the two or more deep ultraviolet LEDs are arranged on the side surface of the treatment instrument so as to be arranged in a line in the direction of introduction of the treatment instrument.

7. The cancer treatment apparatus according to any one of claims 2 to 6, further comprising a control unit for controlling the emission of light from the deep ultraviolet LED, wherein the control unit is located at the proximal end of the treatment instrument, and a conductor connecting the deep ultraviolet LED and the control unit is arranged inside the treatment instrument.

8. 2 mW / cm ２ The cancer treatment device according to any one of claims 1 to 7, characterized in that the deep ultraviolet LED is configured to irradiate the affected area with deep ultraviolet light at the above deep ultraviolet irradiance for 30 to 60 seconds.

9. A cancer treatment device according to any one of claims 1 to 8, characterized in that it is used for the treatment of adenocarcinoma.

10. The cancer treatment device according to any one of claims 1 to 8, characterized in that it is used for the treatment of pancreatic cancer or biliary tract cancer.

Images